CERTIFICATE UNDER 37 CFR § 1.10 OF MAILING BY "EXPRESS MAIL"

EV 847359291 US

October 19, 2006

USPS Express Mail Label Number

Date of Deposit

I hereby certify that this correspondence is being deposited with the United States Postal Services "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated above and is addressed to Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

O 1 P & 19 2006 5

By: Sarah M. Barnett

PATENT Customer No. 22,852

Attorney Docket No. 06843.0028-02000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Tsutomu ARAKAWA et al.) Group Art Unit: 1642
Application No.: 09/994,068) Examiner: Laura B. GODDARD
Filed: November 27, 2001)
For: ANTIBODY-INDUCED APOPTOSIS) Confirmation No.: 8561)

MAIL STOP RCE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the enclosed IDS Form PTO/SB/08. This Information Disclosure Statement is being filed with a Request for Continued Examination.

Copies of the listed documents are enclosed. Applicant respectfully requests that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the enclosed form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed

Application No. 09/994,068 Attorney Docket No. 06843.0028-02000

documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the claimed invention over the listed documents should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to Deposit Account No. 06-0916.

By:

Respectfully submitted, FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.

Elisbeth Brode

Dated: October 19, 2006

Elisabeth Jaffe Barek Reg. No. 46,797 Customer No. 22,852

CERTIFICATE UNDER 37 CFR § 1.10 OF MAILING BY "EXPRESS MAIL"

EV 847359291 US	October 19, 2006		
USPS Express Mail Label Number	Date of Deposit		
I hereby certify that this correspondence is being deposited with the term of the CFR § 1.10 on the date indicated above and is addressed to Mail State By: By: Sar	United States Postal Services "Express p RCE, Commissioner for Patents, and M. Barnett	ess Mail Post Office to Addressee" service under 37 P.O. Box 1450, Alexandria, VA 22313-1450.	
ODS Porce PTO/SB/08: Substitute for form 1449A/PTO	Complete if Known		
	Application Number	09/994,068	
INFORMATION DISCLOSURE	Filing Date	November 27, 2001	
1 9 200STATEMENT BY APPLICANT	First Named Inventor	Tsutomu ARAKAWA	
L' L'ILITERI DI AFFEICANT	Art Unit	1642	
(Use as many sheets as necessary)	Examiner Name	Laura B. GODDARD	

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner	Cite	Document Number	Issue or	Name of Patentee or	Pages, Columns, Lines, Where
Initials* No.	Number-Kind Code (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	
		-			

Attorney Docket Number

06843.0028-02000

	FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No.	Foreign Patent Document Country Code Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation
					:	

NON PATENT LITERATURE DOCUMENTS				
Examiner Cite Initials No.		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
		DESHANE et al., "Intracellular single-chain antibody directed against erbB2 down-regulates cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cells lines," Gene Therapy, 1: 332-337 (1994).		
		GEORGE et al., "Redirection of T cell-mediated cytotoxicity by a recombinant single-chain fv molecule," Journal of Immunology, 152: 1802-1811 (1994).		
,		GRUBER et al., "Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in Escherichia coli," Journal of Immunology, 152: 5368-5374 (1994).		
		HARRIS et al., "The induction of apoptosis in human mammary luminal epithelial cells by expression of activated c-neu and its abrogation by glucocorticoids," British Journal of Cancer, 72: 386-392 (1995).		
		KYAKUMOTO et al., "Co-expression of epidermal growth factor-receptor and c-erb B-2 proto-oncogene product in human salivary-gland adenocarcinoma cell line HSG and the implications for HSG cell autocrine growth," Archives of Oral Biology, 39(7): 569-580 (1994).		
-		LIPPMAN et al., "The role of the erbB2 receptor and its ligands in human breast cancer," Journal of Immunotherapy, 14(4): 369 (1993).		

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.